source
- Merck and Moderna’s melanoma vaccine success spurs five rivals to chase personalized cancer vaccine breakthroughMerck and Moderna announced that their mRNA‑based cancer vaccine, given together with Merck’s Keytruda, extended progression‑free survival in patients with cutaneous melanoma in a late‑stage trial.…
- Cyclic peptide drugs gain traction as AI and hybrid synthesis aim to overcome manufacturing hurdlesOral cyclic peptides are attracting attention because they promise the convenience of small‑molecule drugs while delivering antibody‑like selectivity, a combination that is fueling interest after t…